title: A dopamine receptor d2-type agonist attenuates the ability of stress to alter sleep in mice.
abstract: Although sleep disruptions that accompany stress reduce quality of life and deteriorate health, the mechanisms through which stress alters sleep remain obscure. Psychological stress can alter sleep in a variety of ways, but it has been shown to be particularly influential on rapid eye movement (REM) sleep. Prolactin (PRL), a sexually dimorphic, stress-sensitive hormone whose basal levels are higher in females, has somnogenic effects on REM sleep. In the current study, we examined the relationship between PRL secretion and REM sleep after restraint stress to determine whether: 1) the ability of stress to increase REM sleep is PRL-dependent, and 2) fluctuating PRL levels underlie sex differences in sleep responses to stress. Because dopamine D2 receptors in the pituitary gland are the primary regulator of PRL secretion, D2 receptor agonist, 1-[(6-allylergolin-8β-yl)-carbonyl]-1-[3-(dimethylamino) propyl]-3-ethylurea (cabergoline), was used to attenuate PRL levels in mice before 1 hour of restraint stress. Mice were implanted with electroencephalographic/electromyographic recording electrodes and received an ip injection of either 0.3-mg/kg cabergoline or vehicle before a control procedure of 1 hour of sleep deprivation by gentle handling during the light phase. Six days after the control procedure, mice received cabergoline or vehicle 15 minutes before 1 hour of restraint stress. Cabergoline blocked the ability of restraint stress to increase REM sleep amount in males but did not alter REM sleep amount after stress in females even though it reduced basal REM sleep amount in female controls. These data provide evidence that the ability for restraint stress to increase REM sleep is dependent on PRL and that sex differences in REM sleep amount may be driven by PRL.
authors.affiliation: Neuroscience Institute (F.J., J.C.E., N.S.W., K.N.P.), Department of Neurobiology, Morehouse School of Medicine, Atlanta, Georgia 30310; and Biology Department (J.J.M.), Armstrong State University, Savannah, Georgia 31419.
authors.forename: F
authors.initials: F
authors.lastname: Jefferson
authors.forename: J C
authors.initials: JC
authors.lastname: Ehlen
authors.forename: N S
authors.initials: NS
authors.lastname: Williams
authors.forename: J J
authors.initials: JJ
authors.lastname: Montemarano
authors.forename: K N
authors.initials: KN
authors.lastname: Paul
mesh_terms: D000818:Animals; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000494:pharmacology* / Q000627:therapeutic use; D004569:Electroencephalography; D004873:Ergolines / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011388:Prolactin / Q000097:blood; D017448:Receptors, Dopamine D2 / Q000819:agonists*; D012149:Restraint, Physical; D012890:Sleep / Q000187:drug effects* / Q000502:physiology; D012892:Sleep Deprivation / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D013315:Stress, Psychological / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D017448:Receptors, Dopamine D2; D011388:Prolactin; D000077465:Cabergoline